Cover Image

Application of Proteomics in Cancer Study

Mona Zamanian-Azodi, Mostafa Rezaei-Tavirani, Amir Mortazavian, Reza Vafaee, Majid Rezaei-Tavirani, Hakimeh Zali, Masoud Soheili- Kashani


Cancer is one of the most malignant diseases in the world, accounting for 7.6 million deaths (around 13% of all deaths) in 2008 based on WHO reports. Early detection of cancer is vital due to its final control and prevention. Despite advances in diagnostic strategies, they have not the required sensitivity and specificity for prognosis. During the last decays, one of the most challenges for cancer research is to determine biological basis of this malignancy as a characteristic agents for an early-stage cancer. Understanding these agents requires molecular level examination of the disease followed by analysis of protein networks and their interactions in cells, signaling events among cancer cells, interactions among the cancer cells, and the tumor microenvironment. Proteomics as one of the modern areas of biochemistry holds great promise in cancer study. Inasmuch as, proteome reflects the real state of a cell, tissue or organism, it is expected to achieve more accurate tumor markers for disease diagnosis and therapeutic monitoring. In fact, the utility of this innovative large-scale proteome analyzer has shown significant prospective in biomarker discovery, patient monitoring, drug targeting and cell signaling; moreover, advances in the field of proteomics will provide new insight into the molecular complexity of the disease process, and enable the development of tools to help in treatment as well as in detection and prevention. In this review, proteomics approaches in cancer studies have been represented and discussed.


Biomarker Discovery; Cancer; Proteomics; Diagnosis

Full Text:



Petersen PE. The world oral health report 2003: Continuous improvement of oral health in the 21st century–the approach of the who global oral health programme. Community Dentistry and oral epidemiology. 2008, 31:3-24

John M. Koomen EBH, Gerold Bepler, Rebecca Sutphen, Elizabeth R. Remily-Wood, Kaaron Benson, Mohamad Hussein, Lori A. Hazlehurst, Timothy J. Yeatman, Lynne T. Hildreth, Thomas A. Sellers, Paul B. Jacobsen, David A. Fenstermacher and William S. Dalton. Proteomic contributions to personalized cancer care. MCP. 2008, 11:1780-1794

Anderson NL AN. .Proteome and proteomics: New technologies, new concepts, and new words. Electrophoresis. 1998, 19:1853–1861

Lakhani SR AA. Microarray and histopathological analysis of tumoursthe future and the past? Nat Rev Cancer. 2001, 1:151–157

Donato P CF, Tranchida PQ, Dugo P, Mondello L,. Mass spectrometry detection in comprehensive liquid chromatography basic concepts, instrumental aspects, applications and trends. Mass Spectrom Rev. 2012, 9:3166–3196

Schlegel MARaW. Proteomics in cancer. Advances in Clinical Chemistry. 2007, 44:103-142.

Emily I. Chen JRYI. Cancer proteomics by quantitative shotgun proteomics. molecular Oncology. 2007:144-159

Blackstock WP WM. Proteomics: Quantitative and physical mapping of cellular protein. Trends Biotechnol. 1999, 17:121-127

Zhang Z, Chan DW. Cancer proteomics: In pursuit of “true” biomarker discovery. Cancer Epidemiology Biomarkers & Prevention. 2005, 14:2283-2286

Hanash S, Taguchi A. The grand challenge to decipher the cancer proteome. Nature reviews cancer. 2010, 10:652-660

O'Farrell PHJ. High resolution two-dimensional electrophoresis of proteins. . Biol. Chem. 1974, 250:4007–4021

Mishra NC. Introduction to proteomics. Canada: Wiley; 2010.

MRT. Fundamental and methods in biophysics Iran: Andishe Zohoor; 2012.

Mariana Guergova-Kuras IK, William Hempel, Nadège Tardieu, János,Kádas, Carole Malderez-Bloes, Anne Jullien, Yann Kieffer,Marina Hincapie, András,Guttman, Eszter Csánky, Balázs Dezső, Barry L. Karger and László Takács. Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries. Mol Cell Proteomics. 2011, 10

Nawin C Mishra. Introduction to proteomics. Wiley; 2010.

Sayed S. Daoud. Cancer proteomics from bench to bed. Humana Press; 2008.

Olsen JV, Blagoev, B., Gnad, F., Macek, B., Kumar, C., Mortensen, P., Mann, M. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. . Cell. 2006, 127:635–648.

Liu Y, Patricelli, M.P., Cravatt, B.F. . Activity-based protein profiling: The serine hydrolases. Proc. Natl. Acad. Sci. USA. 1999, 96:14694–14699.

Srinivas PR KB, Srivastava S. . Trends in biomarker research for cancer detection. 2001, 2:698-704.

: SD. Emerging molecular markers of cancer. . Nat Rev Cancer. 2002, 2:210-219.

Engwegen JY, Gast M-CW, Schellens JH, Beijnen JH. Clinical proteomics: Searching for better tumour markers with seldi-tof mass spectrometry. Trends in Pharmacological Sciences. 2006, 27:251-259

Albertson DG, Collins, C., McCormick, F., Gray, J.W. . Chromosome aberrations in solid tumors. Genet. 2003, 34:369–376.

Birchmeier C, Birchmeier, W., Gherardi, E., Vande Woude, G.F. Met, . Metastasis, motility and more. Rev. Mol. Cell. Biol. 2003, 4:915–925

Druker BJDAKAl. Imatinib as aparadigm of targeted therapies. J. Clin. Oncol. 2003, 21:239–245

Blume-Jensen P, and Hunter, T. Oncogenic kinase signaling. Nature. 2001, 411:355–365.

Pawlik TM K. The evolving role of proteomics in the early detection of breast cancer. HM Int J Fertil Womens Med. 2005, 50:212-216

Settleman UMaJ. Personalized cancer therapy with selective kinase inhibitors: An emerging paradigm in medical oncology. JCO. 2009, 32:5650-5659

Bantscheff M, Scholten A, Heck AJR. Revealing promiscuous drug–target interactions by chemical proteomics. Drug Discovery Today. 2009, 14:1021-1029

Semmes OJ MG, Ward M. J Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer. Cell Biochem. 2006, 98:496–503

MA. L. Finding new drug targets in the 21st century. Drug Discov Today. 2005, 10:1683–1687

Mishra NC. Introduction to proteomics. Wiley; 2010.

Yu J, Hu S, Wang J, Wong GK, Li S, Liu B, Deng Y, Dai L, Zhou Y, Zhang X, Cao M, Liu J, Sun J, Tang J, Chen Y, Huang X, Lin W, Ye C, Tong W, Cong L, Geng J, Han Y, Li L, Li W, Hu G, Li J, Liu Z, Qi Q, Li T, Wang X, Lu H, Wu T, Zhu M, Ni P, Han H, Dong W, Ren X, Feng X, Cui P, Li X, Wang H, Xu X, Zhai W, Xu Z, Zhang J, He S, Xu J, Zhang K, Zheng X, Dong J, Zeng W, Tao L, Ye J, Tan J, Chen X, He J, Liu D, Tian W, Tian C, Xia H, Bao Q, Li G, Gao H, Cao T, Zhao W, Li P, Chen W, Zhang Y, Hu J, Liu S, Yang J, Zhang G, Xiong Y, Li Z, Mao L, Zhou C, Zhu Z, Chen R, Hao B, Zheng W, Chen S, Guo W, Tao M, Zhu L, Yuan L, Yang H. {a draft sequence of the rice genome (oryza sativa l. Ssp. Indica)}. Science. 2002, 296:79-92

Idikio HA. Human cancer classification: A systems biology- based model integrating morphology, cancer stem cells, proteomics, and genomics. Journal of Cancer. 2011, 2:107-115

Golub T SD, Tamayo P. . Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science. 1999, 286:531-537

Stelow E S-LR, Bao F, and Garcia J, Klimstra D. American J Surgical Pathology Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine carcinoma. . 2010, 34:510-518

Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nature reviews cancer. 2006, 6:735-741

Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS biology. 2004, 2:e108

Van De Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ. A gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medicine. 2002, 347:1999-2009

Hirano T, Fujioka K, Franzà B. Relationship between ta01 and ta02 polypeptides associated with lung adenocarcinoma and histocytological features. British journal of cancer. 1997, 75:978

George J, Singh R, Mahmood Z, Shukla Y. Toxicoproteomics: New paradigms in toxicology research. Toxicology mechanisms and methods. 2010, 20:415-423

Wetmore BA, Merrick BA. Invited review: Toxicoproteomics: Proteomics applied to toxicology and pathology. Toxicologic pathology. 2004, 32:619-642

Khodarahmi G, Jafari E, Hakimelahi G, Abedi D, Rahmani M, Hassanzadeh F. Synthesis of some new quinazolinone derivatives and evaluation of their antimicrobial activities. Iranian Journal of Pharmaceutical Research. 2012, 11:789-797

George J, Shukla Y. Pesticides and cancer: Insights into toxicoproteomic-based findings. Journal of proteomics. 2011,

Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: Lung cancer classification in the age of targeted therapy. Journal of clinical oncology. 2005, 23:3219-3226

Mehmood N, Zubair M, Rızwan K, Rasool N, Shahid M, Ahmad V. Antioxidant, antimicrobial and phytochemical analysis of cichorium intybus seeds extract and various organic fractions. Iranian Journal of Pharmaceutical Research. 2012,

Rajapakse JC, Duan KB, Yeo WK. Proteomic cancer classification with mass spectrometry data. American Journal of PharmacoGenomics. 2005, 5:281-292

Daoud SS. Cancer proteomics from bench to bed. 2008:59

Fella K, Glückmann M, Hellmann J, Karas M, Kramer PJ, Kröger M. Use of two‐dimensional gel electrophoresis in predictive toxicology: Identification of potential early protein biomarkers in chemically induced hepatocarcinogenesis. Proteomics. 2005, 5:1914-1927

Kang MJ, Lee DY, Joo WA, Kim CW. Plasma protein level changes in waste incineration workers exposed to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. Journal of proteome research. 2005, 4:1248-1255

Ma Y, Visser L, Roelofsen H, de Vries M, Diepstra A, van Imhoff G, van der Wal T, Luinge M, Alvarez-Llamas G, Vos H. Proteomics analysis of hodgkin lymphoma: Identification of new players involved in the cross-talk between hrs cells and infiltrating lymphocytes. Blood. 2008, 111:2339-2346

Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Targeted therapy in breast cancer the her-2/neu gene and protein. Molecular & Cellular Proteomics. 2004, 3:379-398

Di Leo A, Chan S, Paesmans M, Friedrichs K, Pinter T, Cocquyt V, Murray E, Bodrogi I, Walpole E, Lesperance B. Her-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast cancer research and treatment. 2004, 86:197-206

Righetti PG CA, Antonucci F, Piubelli C, Cecconi D, Campostrini N, Rustichelli C, Antonioli P, Zanusso G, Monaco S, Lomas L, Boschetti E. Proteome analysis in the clinical chemistry laboratory: Myth or reality? Clin Chim Acta. 2005, 357:123-139.

Franzén B, Iwabuchi H, Kato H, Lindholm J, Auer G. Two‐dimensional polyacrylamide gel electrophoresis of human lung cancer: Qualitative aspects of tissue preparation in relation to histopathology. Electrophoresis. 1991, 12:509-515

Stewart BW, Kleihues P. World cancer report. IARC press Lyon; 2003.

Okuzawa K, Franzén B, Lindholm J, Linder S, Hirano T, Bergman T, Ebihara Y, Kato H, Auer G. Characterization of gene expression in clinical lung cancer materials by two‐dimensional polyacrylamide gel electrophoresis. Electrophoresis. 1994, 15:382-390

Bergman AC, Benjamin T, Alaiya A, Waltham M, Sakaguchi K, Franzén B, Linder S, Bergman T, Auer G, Appella E. Identification of gel‐separated tumor marker proteins by mass spectrometry. Electrophoresis. 2000, 21:679-686

Yu JK, Chen YD, Zheng S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World Journal of Gastroenterology. 2004, 10:3127-3131

MAURYA P, MELEADY P, DOWLING P, CLYNES M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer research. 2007, 27:1247-1255

Ueda K. Proteome analysis of autoantibodies in sera of patients with cancer. Rinsho Byori. 2005, 53:437-445

Pan J, Chen HQ, Sun YH, Zhang JH, Luo XY. Comparative proteomic analysis of non-small-cell lung cancer and normal controls using serum label-free quantitative shotgun technology. Lung. 2008, 186:255-261

Lu QY, Yang Y, Jin YS, Zhang ZF, Heber D, Li FP, Dubinett SM, Sondej MA, Loo JA, Rao JY. Effects of green tea extract on lung cancer a549 cells: Proteomic identification of proteins associated with cell migration. Proteomics. 2009, 9:757-767

Rahman SMJ, Gonzalez AL, Li M, Seeley EH, Zimmerman LJ, Zhang XJ, Manier ML, Olson SJ, Shah RN, Miller AN. Lung cancer diagnosis from proteomic analysis of preinvasive lesions. Cancer research. 2011, 71:3009-3017

Somiari RI, Somiari S, Russell S, Shriver CD. Proteomics of breast carcinoma. Journal of Chromatography B. 2005, 815:215-225

Azodi MZ, Dolat E, Ardestani H, Mousavi M, Shadloo A. Breast cancer: Genetics, risk factors, molecular pathology and treatment. Journal of Paramedical Sciences (JPS) Winter. 2013, 4:2008-4978

Luo Y, Zhang J, Liu Y, Shaw AC, Wang X, Wu S, Zeng X, Chen J, Gao Y, Zheng D. Comparative proteome analysis of breast cancer and normal breast. Molecular biotechnology. 2005, 29:233-244

Safaei A, Rezaei-Tavirani M, Sobhi S, Akbari ME. Breast cancer biomarker discovery: Proteomics and genomics approaches. Iranian Journal of Cancer Prevention. 2013, 6:45-53

Nwozo SO. Comparative study of biochemical and nutritional status of breast cancer patients on chemotherapy/radiotherapy in ibadan. American Journal of Cancer Science. 2013, 2:51-60

Celis JE, Moreira JMA, Cabezón T, Gromov P, Friis E, Rank F, Gromova I. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Molecular & Cellular Proteomics. 2005, 4:492-522

Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clinical chemistry. 2002, 48:1296-1304

Mathelin C, Cromer A, Wendling C, Tomasetto C, Rio MC. Serum biomarkers for detection of breast cancers: A prospective study. Breast cancer research and treatment. 2006, 96:83-90

Mendrinos S, Nolen JDL, Styblo T, Carlson G, Pohl J, Lewis M, Ritchie J. Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface‐enhanced laser desorption and ionization‐time of flight mass spectrometry. Cancer Cytopathology. 2005, 105:178-183

Hong HY, Jeon WK, Bae EJ, Kim ST, Lee HJ, Kim SJ, Kim BC. 14-3-3 sigma and 14-3-3 zeta plays an opposite role in cell growth inhibition mediated by transforming growth factor-beta 1. Molecules and cells. 2010, 29:305-309

Cahill MA. Progesterone receptor membrane component 1: An integrative review. The Journal of steroid biochemistry and molecular biology. 2007, 105:16-36

Reymond MA, Sanchez JC, Hughes GJ, Günther K, Riese J, Tortola S, Peinado MA, Kirchner T, Hohenberger W, Hochstrasser DF. Standardized characterization of gene expression in human colorectal epithelium by two‐dimensional electrophoresis. Electrophoresis. 1997, 18:2842-2848

Ambrosino C, Tarallo R, Bamundo A, Cuomo D, Franci G, Nassa G, Paris O, Ravo M, Giovane A, Zambrano N. Identification of a hormone-regulated dynamic nuclear actin network associated with estrogen receptor α in human breast cancer cell nuclei. Molecular & Cellular Proteomics. 2010, 9:1352-1367

Reymond MA, Steinert R, Kähne T, Sagynaliev E, Allal AS, Lippert H. Expression and functional proteomics studies in colorectal cancer. Pathology-Research and Practice. 2004, 200:119-127

Safaei A, Sobhi S, Rezaei-Tavirani M, Zali MR. Genomic and epigenetic instability in colorectal cancer. Iranian Journal of Cancer Prevention. 2013, 6:54-63

Sagynaliev E, Steinert R, Nestler G, Lippert H, Knoch M, Reymond MA. Web‐based data warehouse on gene expression in human colorectal cancer. Proteomics. 2005, 5:3066-3078

Rezaie-Tavirani M, Fayazfar S, Heydari-Keshel S, Rezaee MB, Zamanian- Azodi M, Rezaei-Tavirani M, Khodarahmi R. Effect of essential oil of rosa damascena on human colon cancer cell line sw742. Gastroenterology and Hepatology From Bed to Bench. In Press.

Albrethsen J, Bøgebo R, Gammeltoft S, Olsen J, Winther B, Raskov H. Upregulated expression of human neutrophil peptides 1, 2 and 3 (hnp 1-3) in colon cancer serum and tumours: A biomarker study. Bmc Cancer. 2005, 5:8

Droin N, Hendra JB, Ducoroy P, Solary E. Human defensins as cancer biomarkers and antitumour molecules. Journal of proteomics. 2009, 72:918-927

Bertin S, Samson M, Pons C, Guigonis JM, Gavelli A, Baqué P, Brossette N, Pagnotta S, Ricci JE, Pierrefite-Carle V. Comparative proteomics study reveals that bacterial cpg motifs induce tumor cell autophagy in vitro and in vivo. Molecular & Cellular Proteomics. 2008, 7:2311-2322

Van Houdt WJ, Emmink BL, Pham TV, Piersma SR, Verheem A, Vries R, Fratantoni SA, Pronk A, Clevers H, Rinkes IHMB. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies birc6 as a potential therapeutic target. Molecular & Cellular Proteomics. 2011, 10

De Vries AC, Kuipers EJ. Epidemiology of premalignant gastric lesions: Implications for the development of screening and surveillance strategies. Helicobacter. 2007, 12:22-31

Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009, 472:467-477

Katanoda K, Yako-Suketomo H. Comparison of time trends in stomach cancer incidence (1973–2002) in asia, from cancer incidence in five continents, vols iv–ix. Japanese journal of clinical oncology. 2009, 39:71-72

Jang JSJ, Cho HY, Lee YJ, Ha WS, Kim HW. The differential proteome profile of stomach cancer: Identification of the biomarker candidates. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 2004, 14:491-499

Sinha P, Poland J, Schnölzer M, Celis JE, Lage H. Characterization of the differential protein expression associated with thermoresistance in human gastric carcinoma cell lines. Electrophoresis. 2001, 22:2990-3000

Melle C, Ernst G, Schimmel B, Bleul A, Kaufmann R, Hommann M, Richter KK, Daffner W, Settmacher U, Claussen U. Characterization of pepsinogen c as a potential biomarker for gastric cancer using a histo-proteomic approach. Journal of proteome research. 2005, 4:1799-1804

Hao Y, Yu Y, Wang L, Yan M, Ji J, Qu Y, Zhang J, Liu B, Zhu Z. Ipo-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology. Journal of proteome research. 2008, 7:3668-3677

Zamanian-Azodi M, Rezaie-Tavirani M, Heydari-Kashal S, Kalantari S, Dailian S, Zali H. Proteomics analysis of mkn45 cell line before and after treatment with lavender aqueous extract. Gastroenterology and Hepatology from bed to bench. 2011, 5

Tavirani MR, Jazi FR. Biomarkers detection of basal cell carcinoma.

Green CL, Khavari PA. Targets for molecular therapy of skin cancer. Elsevier; 2004, 14:63-69

Kasparian NA, McLoone JK, Meiser B. Skin cancer-related prevention and screening behaviors: A review of the literature. Journal of behavioral medicine. 2009, 32:406-428

Franssen MEJ, Zeeuwen PLJM, Vierwinden G, Van De Kerkhof PCM, Schalkwijk J, Van Erp PEJ. Phenotypical and functional differences in germinative subpopulations derived from normal and psoriatic epidermis. Journal of investigative dermatology. 2005, 124:373-383

Huang CM, Foster KW, DeSilva T, Zhang JF, Shi Z, Yusuf N, Van Kampen KR, Elmets CA, Tang DC. Comparative proteomic profiling of murine skin. Journal of investigative dermatology. 2003, 121:51-64

Hamideh Moravej AZ, Hakimeh Zali, Mostafa Rezaei-Tavirani,Majid Rezaei- Tavirani, Ferdos Rastegar. Proteomics analysis of basal carcinoma via proteomics approaches. 2009, 69:137-141.

Cheng SL, Liu RH, Sheu JN, Chen ST, Sinchaikul S, Tsay GJ. Toxicogenomics of a375 human malignant melanoma cells treated with arbutin. Journal of biomedical science. 2007, 14:87-105

Hoffman RM. Screening for prostate cancer. New England Journal of Medicine. 2011, 365:2013-2019

Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. Autoantibody signatures in prostate cancer. New England Journal of Medicine. 2005, 353:1224-1235

Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis. 2000, 21:2235-2242

Petricoin EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K. Serum proteomic patterns for detection of prostate cancer. Journal of the National Cancer Institute. 2002, 94:1576-1578

Hood BL, Darfler MM, Guiel TG, Furusato B, Lucas DA, Ringeisen BR, Sesterhenn IA, Conrads TP, Veenstra TD, Krizman DB. Proteomic analysis of formalin-fixed prostate cancer tissue. Molecular & Cellular Proteomics. 2005, 4:1741-1753

Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, van der Kwast T, Mizokami A, Morrissey C, Jarvi K. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Molecular & Cellular Proteomics. 2013, 12:1589-1601

Bigot P, Mouzat K, Lebdai S, Bahut M, Benhabiles N, Tassin GC, Azzouzi A-R, Cussenot O. Quantitative proteomic determination of diethylstilbestrol action on prostate cancer. Asian journal of andrology. 2013,

Laird A, O’Mahony FC, Nanda J, Riddick AC, O’Donnell M, Harrison DJ, Stewart GD. Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome. PloS one. 2013, 8:e60483

Sarto C, Marocchi A, Sanchez J-C, Giannone D, Frutiger S, Golaz O, Wilkins MR, Doro G, Cappellano F, Hughes G, Hochstrasser DF, Mocarelli P. Renal cell carcinoma and normal kidney protein expression. Electrophoresis. 1997, 18:599-604

Sarto C, Valsecchi C, Magni F, Tremolada L, Arizzi C, Cordani N, Casellato S, Doro G, Favini P, Perego RA, Raimondo F, Ferrero S, Mocarelli P, Galli-Kienle M. Expression of heat shock protein 27 in human renal cell carcinoma. PROTEOMICS. 2004, 4:2252-2260

Masui O, White NM, DeSouza LV, Krakovska O, Matta A, Metias S, Khalil B, Romaschin AD, Honey RJ, Stewart R. Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Molecular & Cellular Proteomics. 2013, 12:132-144

Wood S, Rogers M, Cairns D, Paul A, Thompson D, Vasudev N, Selby P, Banks R. Association of serum amyloid a protein and peptide fragments with prognosis in renal cancer. British journal of cancer. 2010, 103:101-111


  • There are currently no refbacks.

AJCS(ISSN 2572-5750)Copyright © 2012-2020. All rights reserved. Published by Ivy Union Publishing, 3204 Valley Rush Dr, Apex, North Carolina 27502, United States